StockData

Orchestra BioMed Holdings, Inc. (OBIO) stock

OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$6.97−0.15 (-2.11%)

Close on Nov 17, 2026Market cap $418.93MP/E –Yield –

Orchestra BioMed r&d expenses

Research and development expenses are spending on new products and technology.

Orchestra BioMed's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.22M, up 26.7% year over year. For fiscal 2025 it was $58.19M, up 35.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$58.19M+35.9%
FY2024Dec 31, 2024$42.80M+26.6%
FY2023Dec 31, 2023$33.82M+54.1%
FY2022Dec 31, 2022$21.95M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.59M+19.8%
Q1 FY2026Mar 31, 2026$15.78M+17.1%
Q4 FY2025Dec 31, 2025$16.82M+53.3%
Q3 FY2025Sep 30, 2025$14.03M+21.0%
Q2 FY2025Jun 30, 2025$13.85M+24.5%
Q1 FY2025Mar 31, 2025$13.48M+48.0%
Q4 FY2024Dec 31, 2024$10.97M+28.9%
Q3 FY2024Sep 30, 2024$11.60M+35.5%
Q2 FY2024Jun 30, 2024$11.13M+30.9%
Q1 FY2024Mar 31, 2024$9.11M+10.4%
Q4 FY2023Dec 31, 2023$8.51M+12.8%
Q3 FY2023Sep 30, 2023$8.56M+45.1%
Q2 FY2023Jun 30, 2023$8.50M+69.0%
Q1 FY2023Mar 31, 2023$8.25M+137.6%
Q4 FY2022Dec 31, 2022$7.54M–
Q3 FY2022Sep 30, 2022$5.90M–
Q2 FY2022Jun 30, 2022$5.03M–
Q1 FY2022Mar 31, 2022$3.47M–

More Orchestra BioMed figures

See a number that looks wrong?